Medtronic presented real-world clinical results that compared glycemic outcomes for 1,736 individuals before and after using the InPen smart1 insulin pen for 90 days with a glucose monitor Medtronic ...
New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses. GALWAY, Ireland, Nov. 20, 2024 ...
CGM technology could become a cornerstone in modern diabetes management. Credit: Halfpoint via Shutterstock. In an advancement for diabetes management, the US Food and Drug Administration (FDA) has ...
Medtronic MDT continues to grab headlines with respect to its Diabetes management business update. Following two back-to-back European approvals last month for its InPen smart insulin pen as well as ...
SAN DIEGO, April 8, 2020 /PRNewswire/ -- Companion Medical, manufacturer of InPen, the FDA-cleared intelligent insulin system for people with diabetes who practice multiple daily injections (MDI), ...
The InPen system uses a smart pen and Bluetooth-enabled app to calculate insulin doses, issue dose reminders, track active insulin and send reports to caregivers. Credit: Companion Medical Companion ...
Companion Medical today confirmed that it has received clearance from the FDA for its InPen bolus calculator for fixed dosing and meal estimation Companion Medical today confirmed that it has received ...
Medtronic (MDT) announced FDA clearance for its new InPen app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera continuous glucose monitor, ...
Medtronic MDT continues to grab headlines with respect to its Diabetes management business update. Following two back-to-back European approvals last month for its InPen smart insulin pen as well as ...
Medtronic plc has reported the launch of the Inpen integrated with real-time Guardian Connect continuous glucose monitoring (CGM) data. Inpen is the first U.S. FDA-cleared smart insulin pen on the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results